PCSK9 anticorps (C-Term)

N° du produit ABIN3032340

Détail du produit anti-PCSK9 anticorps

Antigène: PCSK9 (Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9))

Épitope: C-Term

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp PCSK9 est non-conjugé

Application: Western Blotting (WB), ELISA

Purification: Antigen affinity purified

Immunogène: This PCSK9 antibody was produced from a rabbit immunized with a KLH conjugated synthetic peptide between 654-688 amino acids from the C-terminal region of human PCSK9.

Isotype: Ig Fraction

Information d'application

Indications d'application: Titration of the PCSK9 antibody may be required due to differences in protocols and secondary/substrate sensitivity.\. Western blot: 1:1000

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: In 1X PBS pH 7.4 with 0.09 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Aliquot the PCSK9 antibody and store frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.

Détails sur PCSK9

Antigène: PCSK9 (Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9))

Autre désignation: PCSK9 (PCSK9 Produits)

Synonymes: anticorps FH3, anticorps HCHOLA3, anticorps LDLCQ1, anticorps NARC-1, anticorps NARC1, anticorps PC9, anticorps AI415265, anticorps AI747682, anticorps Narc1, anticorps proprotein convertase subtilisin/kexin type 9, anticorps proprotein convertase subtilisin/kexin type 9 L homeolog, anticorps PCSK9, anticorps pcsk9.L, anticorps pcsk9, anticorps Pcsk9

Sujet: Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway. Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways.

UniProt: Q8NBP7